Evidence map›Paper›PMID 24302957›Full record

ArticleClinical & developmental immunology2013

Treatment with CB2 agonist JWH-133 reduces histological features associated with erectile dysfunction in hypercholesterolemic mice.

Rodrigo Araujo Fraga-Silva, Fabiana Pereira Costa-Fraga, Fabrizio Montecucco, Younouss Faye, Silvia Quintao Savergnini, Sébastien Lenglet, François Mach, Sabine Steffens, Nikolaos Stergiopulos, Robson Augusto Souza dos Santos and 1 more

Open access · goldAbstract read
In one paragraph

Article in Clinical & developmental immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Rodrigo Araujo Fraga-SilvaInstitute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, Station 17, BM 5115, CH-1015 Lausanne, Switzerland.
Fabiana Pereira Costa-Fraga
Fabrizio Montecucco
Younouss Faye
Silvia Quintao Savergnini
Sébastien Lenglet
François Mach
Sabine Steffens
Nikolaos Stergiopulos
Robson Augusto Souza dos Santos
Rafaela Fernandes da Silva
École Polytechnique Fédérale de Lausanne · CHFoundation for laboratory medicine · CHUniversidade Federal de Minas Gerais · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypercholesterolemia is one of the most important risk factors for erectile dysfunction, mostly due to the impairment of oxidative stress and endothelial function in the penis. The cannabinoid system might regulate peripheral mechanisms of sexual function; however, its role is still poorly understood. We investigated the effects of CB2 activation on oxidative stress and fibrosis within the corpus cavernosum of hypercholesterolemic mice. Apolipoprotein-E-knockout mice were fed with a western-type diet for 11 weeks and treated with JWH-133 (selective CB2 agonist) or vehicle during the last 3 weeks. CB2 receptor expression, total collagen content, and reactive oxygen species (ROS) production within the penis were assessed. In vitro corpus cavernosum strips preparation was performed to evaluate the nitric oxide (NO) bioavailability. CB2 protein expression was shown in cavernosal endothelial and smooth muscle cells of wild type and hypercholesterolemic mice. Treatment with JWH-133 reduced ROS production and NADPH-oxidase expression in hypercholesterolemic mice penis. Furthermore, JWH-133 increased endothelial NO synthase expression in the corpus cavernosum and augmented NO bioavailability. The decrease in oxidative stress levels was accompanied with a reduction in corpus cavernosum collagen content. In summary, CB2 activation decreased histological features, which were associated with erectile dysfunction in hypercholesterolemic mice.

Indexed as

AnimalsCannabinoidsDisease Models, AnimalErectile DysfunctionFibrosisHypercholesterolemiaLipidsMaleMiceMice, KnockoutNADPH OxidasesNitric OxideNitric Oxide Synthase Type IIIPenisReactive Oxygen SpeciesReceptor, Cannabinoid, CB21,1-dimethylbutyl-1-deoxy-Delta(9)-THCCannabinoidsLipidsNADPH OxidasesNitric OxideNitric Oxide Synthase Type IIIReactive Oxygen SpeciesReceptor, Cannabinoid, CB2

Identifiers

PMID24302957
PMCPMC3835849
OpenAlexW2095796252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.